Glia maturation factor-β deficiency improves insulin resistance by promoting CARM1-mediated lipid turnover

Area of Science:

• Metabolic disease research
• Molecular endocrinology
• Obesity and diabetes research

Background:

• Insulin resistance (IR) is a key factor in obesity-associated type 2 diabetes, with poorly understood molecular mechanisms.
• Current pharmacological treatments for IR are insufficient, highlighting the need for novel therapeutic targets.

Purpose of the Study:

• To investigate the role of glia maturation factor-beta (GMFB) in regulating systemic insulin resistance.
• To develop and evaluate a GMFB inhibitor for potential therapeutic use.

Main Methods:

• Examined GMFB expression in adipose tissue across species (rats, mice, humans) in relation to IR.
• Utilized Gmfb knockout (KO) models (systemic and adipocyte-specific) to assess effects on IR and lipotoxicity.
• Investigated the molecular mechanism involving GMFB degradation, CARM1 nuclear translocation, and PPARγ coactivation.
• Tested the efficacy of a GMFB inhibitor, DS19, in improving insulin sensitivity.

Main Results:

• GMFB expression in adipose tissue correlates with IR.
• Gmfb depletion in adipocytes improved IR and reduced plasma lipotoxicity by enhancing lipid turnover.
• GMFB degradation via chaperone-mediated autophagy under insulin stimulation was observed.
• Gmfb KO promoted CARM1 nuclear translocation, coactivating PPARγ and improving adipocyte lipid metabolism.
• The GMFB inhibitor DS19 demonstrated significant insulin-sensitizing effects by disrupting the GMFB-CARM1 interaction.

Conclusions:

• Glia maturation factor-beta (GMFB) is identified as a novel systemic regulator of insulin resistance through its control of adipocyte lipid turnover.
• The GMFB inhibitor DS19 represents a promising therapeutic candidate for obesity-induced insulin resistance, warranting further clinical investigation.